Regulation
Compounded Tirzepatide Is Over. Here Is What Replaced It.
Routine compounding of tirzepatide ended in early 2025. The FDA declared the shortage resolved on 2 October 2024, reaffirmed it by declaratory order on 19 December 2024, and enforcement discretion expired on 18 February 2025 for 503A pharmacies and 19 March 2025 for 503B facilities. A federal court upheld the determination in May 2025. The cheap compounded market that defined 2023 and 2024 is closed.
Key takeaways
- Compounding tirzepatide was legal only while the drug sat on the FDA shortage list.
- The shortage was declared resolved in October 2024 and reaffirmed that December.
- Enforcement discretion ended 18 February 2025 (503A) and 19 March 2025 (503B).
- A federal court upheld the FDA's determination in May 2025.
- The live options are now insurance coverage, manufacturer programmes, and direct cash pricing.
| What changed | Tirzepatide removed from the FDA drug shortage list |
|---|---|
| When | 2 October 2024; reaffirmed 19 December 2024 |
| 503A deadline | 18 February 2025 |
| 503B deadline | 19 March 2025 |
| Legal challenge | Upheld by the US District Court, N.D. Texas, May 2025 |
| Evidence status | Verified against the FDA declaratory order |
Why was compounding ever allowed?
Federal law lets compounders prepare what would otherwise be an unlawful copy of an approved drug when that drug appears on the FDA shortage list. Tirzepatide was added in 2022 as demand outstripped supply, and an entire telehealth industry formed in the space that exemption created. Prices of $150 to $300 a month against a brand list price above $1,000 were the direct consequence.
That was always a temporary legal condition rather than a permanent market. When Eli Lilly's production caught up with demand, the exemption's precondition disappeared and the exemption went with it.
What about 'personalised' compounded tirzepatide?
Some sellers continued after the deadlines by adding an ingredient such as vitamin B12 or varying the dose slightly, arguing the result is not an essentially-a-copy product. The FDA has treated preparations close to the approved dose as essentially copies regardless of such additions.
For a buyer, the practical reading is simple. A seller relying on that argument is operating in contested territory, and the product's quality, concentration, and legal standing are all unverified. That is a very different proposition from the shortage-era market, which at least operated under an explicit exemption.
| Date | Event |
|---|---|
| Oct 2024 | FDA removes tirzepatide from the shortage list |
| Dec 2024 | Declaratory order reaffirms resolution |
| Feb 2025 | 503A enforcement discretion ends |
| Mar 2025 | 503B enforcement discretion ends |
| May 2025 | Federal court upholds the FDA |
| Feb 2026 | FDA moves to restrict GLP-1 ingredients in non-approved products |
What replaced it, and what does that cost?
Three pathways. Insurance coverage, where a plan includes a weight-management benefit, which can reduce the monthly cost to a modest copay. Manufacturer savings programmes for commercially insured patients. And the manufacturer's direct cash channel, where Zepbound self-pay runs $299 per month at the starting dose and $449 at maintenance doses of 7.5 mg and above.
Against a retail list price near $1,086 without coverage, the direct channel is a substantial saving. Against compounded pricing at $125 to $300, it is a substantial increase. Both comparisons are true, and which one matters depends on where you are coming from.
| Group | $/month |
|---|---|
| Zepbound self-pay, 2.5 mg | 299 |
| Zepbound self-pay, 7.5 mg+ | 449 |
| Zepbound retail, no coverage | 1086 |
What should someone on a compounded programme do now?
Speak to the prescriber who issued the prescription before changing anything. The transition involves dose continuity and supply as well as cost, and none of it should be self-managed on the basis of a webpage.
Financially, budget for an increase. Anyone who prepaid a multi-month compounded programme before the deadlines also has a fair question about what was supplied afterwards, and that is worth putting in writing to the provider.
What would change the conclusion on this page?
Any of the following would change what this page concludes:
- New primary evidence bearing directly on compounded tirzepatide ended.
- A change to FDA labelling or regulatory position affecting a statement above.
- A verified correction accepted through the corrections process.
- A material change to a captured price, term, or programme condition.
More from the journal: all pieces
What are the limits of what this page can tell you?
Every page on this site rests on a specific published evidence, and that record has boundaries worth stating plainly rather than leaving a reader to discover them. The limitations below are specific to the material presented above.
- The evidence here describes groups, populations, or captured records — it does not describe you, and no page can substitute for a qualified professional.
- Figures carry the date on which they were verified. In a market where terms change frequently, an undated figure functions as a claim about the present that nobody has checked.
- Elements marked Verification Pending are genuinely unknown to this publication rather than merely omitted for brevity, and should not be inferred from surrounding content.
- Where a source conflicts with another, this site shows the conflict rather than resolving it, which means some questions are left open on purpose.
What would change the conclusion on this page?
This page would be revised, with the change recorded in its history, if any of the following occurred:
- New primary evidence bearing directly on compounded tirzepatide is over. here is what replaced it..
- A change to FDA labelling affecting any statement made above.
- A verified correction submitted through the corrections process and accepted on the evidence.
- A material change to a captured record, including a price, term, or regulatory status.
- Completion of a verification currently marked pending, which would replace a gap with a stated fact.
What do the technical terms on this page mean?
Definitions for the 4 technical terms this page uses, including 503A, 503B, GLP-1, compounded — in the specific sense used above.
| 503A | A pharmacy that compounds patient-specific preparations against individual prescriptions. It is licensed by a state board of pharmacy and is not subject to the same federal manufacturing requirements as a 503B facility. |
|---|---|
| 503B | An outsourcing facility that may compound in larger batches without individual prescriptions. It registers with the FDA and is subject to current good manufacturing practice requirements, though registration is still not product approval. |
| GLP-1 | Glucagon-like peptide-1. An incretin hormone that slows gastric emptying, signals satiety to the brain, stimulates glucose-dependent insulin release, and suppresses inappropriate glucagon secretion. |
| compounded | Prepared by a pharmacy rather than manufactured under an approved application. Compounded tirzepatide is not FDA approved and has not been evaluated in any randomised trial. |
Frequently asked questions
Is compounded tirzepatide illegal now?
Routine compounding of tirzepatide as a copy of an approved drug is no longer permitted, because the shortage that allowed it was declared resolved and enforcement discretion expired in early 2025.
Why do some websites still sell it?
Some argue that adding an ingredient or varying the dose makes the product legally distinct. The FDA has treated preparations close to the approved dose as essentially copies regardless.
What is the cheapest legal option now?
For cash payers, the manufacturer's direct channel starting at $299 per month. For anyone with commercial insurance, pursuing coverage is usually worth more than any price comparison.
Should I stop my current medication?
No — not on the basis of a website. Speak to your prescriber about transition options.
Did a court overturn the FDA?
No. The US District Court for the Northern District of Texas upheld the FDA's shortage resolution in May 2025.
Change history
| Date | Change |
|---|---|
| 2026-07-22 | Page published with current dataset snapshot. |
Dates change only for substantive edits, never for cosmetic changes. Corrections: corrections policy.